First Breast Cancer Patient in Japanese Trial Receives Entinostat

First Breast Cancer Patient in Japanese Trial Receives Entinostat
The first patient has been dosed in a pivotal Phase 2 clinical trial in Japan evaluating entinostat as a therapy for hard-to-treat breast cancers. Syndax Pharmaceuticals, which developed the therapy, said the trial (NCT03291886) will cover patients with advanced or recurrent hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancers. A pivotal trial is one that is intended to provide evidence for a

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *